{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T22:35:32Z","timestamp":1769639732865,"version":"3.49.0"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Stomatitis is a relatively common adverse effect of systemic pharmacologic therapy seen in the treatment of various malignancies. When severe, stomatitis has the potential to limit a patient\u2019s ability to tolerate optimal medical therapy and to impact quality of life. There are a variety of etiologies underlying stomatitis, including lichenoid drug eruptions. Herein, we present a novel case of a patient with metastatic renal cell carcinoma treated with pembrolizumab and axitinib who subsequently developed stomatitis consistent with a lichenoid drug reaction on biopsy. Pembrolizumab is known to cause such eruptions, and while there are no known lichenoid reactions reported for axitinib, stomatitis is one of the most common adverse effects of this therapy. In our case, it was not clear which systemic agent was the culprit. Axitinib was initially discontinued at the onset of symptoms. However, after a biopsy revealed lichenoid changes that are typically associated with pembrolizumab, pembrolizumab therapy was also stopped. With drug interruption and systemic glucocorticoid therapy, the patient\u2019s stomatitis eventually improved. However, when axitinib was re-introduced to his treatment regimen, the patient experienced severe worsening of his oral lesions and development of new hand lesions requiring hospital admission. While the exact etiology of the lesions is unknown, the timeline of events appears to indicate a potential role of axitinib. This patient case represents a unique clinical scenario of axitinib contributing to a lichenoid drug eruption and highlights the importance of carefully considering the contributions of each agent in multidrug therapy regimens. Such cases are expected to become more frequent as combination immunotherapies and targeted therapies continue to gain approval across multiple solid tumor malignancies.<\/jats:p>","DOI":"10.3389\/fonc.2025.1495446","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T04:10:23Z","timestamp":1747627823000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case Report: Oral lichenoid mucositis in a patient with metastatic renal cell carcinoma undergoing treatment with pembrolizumab and axitinib"],"prefix":"10.3389","volume":"15","author":[{"given":"Andrew","family":"Wellen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Pierro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karolyn A.","family":"Wanat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariel A.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1318","article-title":"The pathobiology of mucositis","volume":"4","author":"Sonis","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.2009.00953.x","article-title":"Oral lichenoid drug eruption: a report of a pediatric case and review of the literature","volume":"26","author":"Woo","year":"2009","journal-title":"Pediatr Dermatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/j.1601-0825.1997.tb00013.x","article-title":"Oral lichenoid drug eruptions","volume":"3","author":"McCartan","year":"1997","journal-title":"Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14284","article-title":"Oral lichenoid reactions associated with anti-PD-1\/PD-L1 therapies: clinicopathological findings","volume":"31","author":"Sibaud","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/odi.13218","article-title":"Oral immune-related adverse events associated with PD-1 inhibitor therapy: A case series","volume":"26","author":"Shazib","year":"2020","journal-title":"Dis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2011.05113.x","article-title":"Lichen planus and lichenoid drug-induced eruption: a histological and immunohistochemical study","volume":"51","author":"Lage","year":"2012","journal-title":"Int J Dermatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(93)70176-t","article-title":"Lichenoid drug eruptions","volume":"29","author":"Halevy","year":"1993","journal-title":"J Am Acad Dermatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/cco.0000000000000290","article-title":"Dermatologic complications of anti-PD-1\/PD-L1 immune checkpoint antibodies","volume":"28","author":"Sibaud","year":"2016","journal-title":"Curr Opin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.10.062","article-title":"Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management","volume":"80","author":"Coleman","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e13768","DOI":"10.7759\/cureus.13768","article-title":"Pembrolizumab-induced lichenoid dermatitis in a patient with metastatic cancer of unknown primary","volume":"13","author":"Sethi","year":"2021","journal-title":"Cureus"},{"key":"B11","first-page":"192","article-title":"Pembrolizumab: lichenoid dermatitis: 3 case reports","volume":"1571","year":"2015","journal-title":"Reactions Weekly; Auckland"},{"key":"B12","doi-asserted-by":"publisher","first-page":"10","DOI":"10.5070\/D3259045515","article-title":"Digital ulcerative lichenoid dermatitis in a patient receiving anti-PD-1 therapy","volume":"25","author":"Martinez-Domenech","year":"2019","journal-title":"Dermatol Online J"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0531","article-title":"Resolution of pembrolizumab-associated steroid-refractory lichenoid dermatitis with cyclosporine","volume":"24","author":"Fixsen","year":"2019","journal-title":"Oncologist"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.5070\/d3265048774","article-title":"Resolution of pembrolizumab-associated lichenoid dermatitis with a single dose of methotrexate","volume":"26","author":"Varma","year":"2020","journal-title":"Dermatol Online J"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.annder.2022.11.012","article-title":"Oral mucosal toxicities induced by immune checkpoint inhibitors: Clinceal features and algorithm management","volume":"150","author":"Vigarios","year":"2023","journal-title":"Ann Dermatol Venereol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.oooo.2020.06.014","article-title":"Severe oral erosive lichenoid reaction to pembrolizumab therapy","volume":"130","author":"Bhattacharyya","year":"2020","journal-title":"Surgery  Medicine  Pathol  Radiol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2020.11.023","article-title":"Severe mucositis secondary to pembrolizumab: reports of two cases, review of literature, and an algorithm for management","volume":"79","author":"Huntley","year":"2021","journal-title":"J  Maxillofacial Surg"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2019-0162","article-title":"Severe chronic nonlichenoid oral mucositis in pembrolizumab patients: new cases and a review of the literature","volume":"12","author":"Amy","year":"2020","journal-title":"Immunotherapy"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-021-05993-5","article-title":"Oral mucositis \u2013 case series of a rare adverse effect associated with immunotherapy","volume":"29","author":"Sheth","year":"2021","journal-title":"Supportive Care Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"212516","DOI":"10.7573\/dic.212516","article-title":"Cutaneous side effects of molecularly targeted therapies for the treatment of solid tumors","volume":"8","author":"Cubero","year":"2018","journal-title":"Drugs Context"},{"key":"B21","doi-asserted-by":"publisher","first-page":"5035217","DOI":"10.1155\/2018\/5035217","article-title":"Stomatitis and VEGFR-Tyrosine Kinase Inhibitors (VR-TKIs): A review of current literature in 4369 patients","volume":"2018","author":"Arena","year":"2018","journal-title":"BioMed Res Int"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcsup.2013.07.016","article-title":"Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors","volume":"11","author":"Schmidinger","year":"2013","journal-title":"EJC Suppl"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01259","article-title":"Paraneoplastic pemphigus: paraneoplastic autoimmune disease of the skin and mucosa","volume":"10","author":"Kim","year":"2019","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"New Engl J Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1495446\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T04:10:24Z","timestamp":1747627824000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1495446\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":24,"alternative-id":["10.3389\/fonc.2025.1495446"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1495446","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,19]]},"article-number":"1495446"}}